13-valent pneumococcal conjugate vaccine (PCV13)

Jefferies, Johanna M.C., Macdonald, Emily, Faust, Saul N. and Clarke, Stuart C. (2011) 13-valent pneumococcal conjugate vaccine (PCV13). Human Vaccines & Immunotherapeutics, 7 (10), 1012-1018. (doi:10.4161/hv.7.10.16794). (PMID:21941097)

Abstract

The thirteen valent pneumococcal conjugate vaccine (PCV13, Prevenar 13Ô) is the broader coverage successor to the highly effective seven valent vaccine (PCV7, PrevenarÔ) which has reduced rates of pneumococcal disease in many countries. Despite the success of PCV7, pneumococcal disease due to non-PCV7 serotypes remains a threat in many settings, in particular many developing countries with a high burden of pneumococcal disease where serotype 1 and 5 are among the most common serotypes. Disease due to certain non-PCV7 serotypes, in particular serotype 19A has also begun to increase in incidence in countries with widespread use of PCV7. PCV13 consists of thirteen pneumococcal capsular polysaccharides individually conjugated to the diphtheria-derived protein carrier CRM197. In addition to serotypes 4, 6B, 9V, 14, 18C, 19F and 23F included in PCV7, PCV13 also includes serotypes 1, 3, 5, 6A, 7F and 19A. PCV13 was licensed on the basis of non-inferiority trials and has proved to be at least as safe and effective as PCV7. PCV13 replaced PCV7 in the childhood immunisation schedules of the USA and UK in 2010 and is being rolled out to an increasing number of developing countries during 2011. Here we review the current literature regarding this vaccine, describing safety, efficacy, global serotype coverage and use and future directions.

This record has no associated files available for download.

Contributors

Author: Saul N. Faust

Author: Stuart C. Clarke

Download statistics